Skip to main content

EULAR 2023: Featured Industry Presentations

EULAR 2023 opens tomorrow, Wednesday May 31st, with hundreds of novel presentations and pivotal clinical trials, many being featured industry sponsored clinical trials and research on their novel agents. Below is a collection of the featured abstracts, and presentation times from EULAR 2023. 

You can search the EULAR site for these abstracts and other research that may interest you - click here.

Abbvie

Industry Sponsor Abstract # Date Presentation Title
Abbvie POS0849 Thurs, 1 June; 14:45-15:45 CEST Long-Term Safety and Efficacy of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Five-Year Data From the SELECT-COMPARE Study
  POS1541 Sat, 3 June; 10:30-11:30 CEST Long-Term Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: Three-Year Results from the Phase 3 SELECT-PsA 1 Study
  POS1122 Fri, 2 June; 9:30-10:30 CEST Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondylitis and an Inadequate Response to Biologic DMARD Therapy: One-Year Results from a Phase 3 Study
  OP0139    A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) (SLEek)

 

 

 

 

 

 

 

 

 

 

 

Industry Sponsor Abstract # Date Presentation Title
BMS POP0130  Thurs, 1 June ABATACEPT IN INDIVIDUALS AT RISK OF DEVELOPING RHEUMATOID ARTHRITIS: RESULTS FROM THE ARTHRITIS PREVENTION IN THE PRE-CLINICAL PHASE OF RA WITH ABATACEPT (APIPPRA) TRIAL

 

 

 

 

 

Industry Sponsor Abstract # Date Presentation Title
UCB POS0231 Friday, June 2, 12:00–13:30 CEST

Sustained efficacy and safety of bimekizumab in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: Results from the phase 3 BE COMPLETE study and its open-label extension up to 1 year

  POS0246  Friday, June 2, 12:00–13:30 CEST

Bimekizumab reduced MRI inflammatory lesions in patients with axial spondyloarthritis: Week 52 results from the BE MOBILE 1 and BE MOBILE 2 phase 3 studies

  POS1537 Saturday, June 3, 10:30–11:30 CEST

Bimekizumab efficacy and safety in biologic DMARD-naïve patients with psoriatic arthritis was consistent with or without methotrexate: 52-week results from the phase 3 active-reference study BE OPTIMAL

  POS0115 Thursday, June 1, 12:00–13:30 CEST

Dapirolizumab pegol efficacy by subgroups in patients with systemic lupus erythematosus: A post hoc analysis of phase 2 clinical trial data

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Industry Sponsor Abstract # Date Presentation Title
Horizon OP0143 June 1, 11:35-11:45 a.m. CEST Efficacy and Safety of Dazodalibep (VIB4920/HZN4920) in Subjects with Sjögren’s Syndrome: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study

 

 

 

 

 

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.